Kyle R. Swartz

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Kyle

Last Name

Swartz

NPI

1871086843

Faculty ID

18356

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

8632

Biography

<p>Kyle Swartz, DO, is an attending physician at Montefiore Einstein and Assistant Professor, Medicine at our Albert Einstein College of Medicine. Dr. Swartz assists patients with all lung diseases and has a particular focus on interstitial lung disease. He is also interested in advanced critical care ultrasound in the intensive care unit.</p><p>After obtaining his Bachelor of Science in biology from The Ohio State University in 2013, Dr. Swartz earned his Doctor of Osteopathic Medicine at Touro College of Osteopathic Medicine in 2018. He completed his internal medicine residency at Montefiore Einstein in 2021, followed by a pulmonary and critical care fellowship in 2024.</p><p>Dr. Swartz has focused his research on advanced lung diseases and advanced critical care ultrasound. His work has been published in numerous peer-reviewed manuscripts, articles, and abstracts, and he has shared it through oral presentations, poster presentations, and videos.</p><p>Dr. Swartz is board certified in Internal Medicine and Pulmonary Disease through the American Board of Internal Medicine. He is a committee member of the CHEST Ultrasound and Imaging Section Network of the American College of Chest Physicians.</p>

Is Open Scheduling

On

Matthew G. Nevulis

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Matthew

Last Name

Nevulis

NPI

1962934596

Faculty ID

17872

CMO Specialties

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

123252

Is Open Scheduling

Off

Ayush Sutaria

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/8e635770-6415-11ee-b895-55c3e0ecfd74.jpg

First Name

Ayush

Last Name

Sutaria

NPI

1396199352

Faculty ID

17812

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

186411

Is Open Scheduling

Off

Jose Moonjely Davis

https://assets.montefioreeinstein.org/profiles/images/17613-jose-moonjely-davis.jpg

First Name

Jose

Last Name

Moonjely Davis

NPI

1972983336

Faculty ID

17613

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

180097

Visit Type ID

2542

Is Open Scheduling

On

Heyi Li

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/cbc2d3f0-3eb1-11ed-a405-bd68d3fd2c32.jpg

First Name

Heyi

Last Name

Li

NPI

1265986178

Faculty ID

17368

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

173372

Biography

<p>Heyi Li, MD, is an attending physician and Assistant Professor, Pulmonary and Critical Care Medicine at Montefiore Einstein. Her clinical focus is on the management of acute and chronic disorders of the lung and breathing, such as chronic obstructive lung diseases, asthma, interstitial lung diseases, infectious lung diseases and lung nodules. She performs airway and chest procedures including bronchoscopies and thoracentesis, and also provides consultations on smoking cessation and respiratory rehabilitation.</p><p>After earning her Bachelor of Engineering degree at Zhejiang University, Hangzhou, China in 2011, she continued her education with the institution&rsquo;s School of Medicine, earning her Doctor of Medicine in 2015. Dr Li&rsquo;s postdoctoral training brought her to the United States, completing a three-year residency in internal medicine at John H. Stroger Jr. Hospital of Cook County in 2019 and a pulmonary and critical care fellowship at Mayo Clinic at Rochester, Minnesota in 2022.</p><p>Dr. Li&rsquo;s clinical research focuses on care delivery research and implementation science. Her goal is to develop a mature line of inquiry in implementation science, focused on both conceptual frameworks and pragmatic implementation strategies. She has shared her work through peer-reviewed journals and has presented it at regional and national conferences. Dr. Li has also been a periodic reviewer for <em>Critical Care Medicine</em> and the <em>American Journal of Respiratory and Critical Care Medicine</em>.</p><p>Dr. Li is board certified in Internal Medicine and Pulmonary Medicine by the American Board of Internal Medicine. She is a member of the American College of Chest Physicians, the American Thoracic Society and the Society of Critical Care Medicine.</p>

Visit Type ID

2542

Is Open Scheduling

On

Sarah Sungurlu

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/8d27d5c0-7e34-11ec-abab-b971dcc17ab8.jpg

First Name

Sarah

Last Name

Sungurlu

NPI

1174819478

Faculty ID

17214

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

165589

Visit Type ID

2542

Is Open Scheduling

On

Kate R. Steinberg

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/05b61a40-891d-11ec-a48a-e9e0c9e20faa.jpg

First Name

Kate

Last Name

Steinberg

NPI

1528488459

Faculty ID

16973

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

141643

Visit Type ID

2542

Is Open Scheduling

On

Simon D. Spivack

https://assets.montefioreeinstein.org/profiles/images/Spivack_Simon_MD_2x.jpg

First Name

Simon

Last Name

Spivack

NPI

1366438475

Faculty ID

11003

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>&nbsp;</p>
<p>Focusing diagnostics and therapeutics on those most likely to benefit is a key to successful intervention&nbsp;at both the public health and clinical levels. The translational goal of the Spivack laboratory is to identify individuals at particularly high risk for lung malignancy, and selected non-malignant lung diseases, upon whom to focus smoking/toxin exposure cessation (primary prevention), chemoprevention (secondary prevention), and early disease detection efforts (disease screening, tertiary prevention).</p>
<p>The laboratory is currently exploring individual Gene x Environment signatures as susceptibility markers by exploring quantitative gene (mRNA) expression phenotypes, and the DNA sequence, methylation, microRNA, and other epigenetic features potentially underlying these expression phenotypes, <em>in vitro</em> and in human populations. This is performed in the setting of defined tobacco, diet, and other exposures. There are both mechanistic and translational components to the studies.&nbsp;</p>
<p><br /><strong>Mechanistically</strong>, the role of epigenetic variation in promoter regions in the 5' and 3' regulatory regions of carcinogenesis and oxidant pathway genes is being explored <em>in vitro</em>, using human genomic DNA reporter constructs, and native gene regulation models. High resolution technologies include the realtime quantitation of native mRNA and microRNA by the laboratory's RNA-specific strategy (<em>patented</em>); the&nbsp;tagged-bisulfite genomic sequencing strategy to determine single base resolution CpG methylation status (tBGS, <em>patented</em>);&nbsp;&nbsp;an experimental strategy for assaying microRNA binding to mRNA, for determining the role of miRNA in candidate gene regulation&nbsp;(<em>patented</em>); and evaluation of functional consequences of DNA&nbsp;methylation detail, using a novel patch reporter construct (<em>patented</em>).&nbsp; A new method to engineer methyl-cytosines into the epigenome has recently been developed.</p>
<p>Whole (epi)genome approaches to identify molecular events unique to lung cancer&nbsp;are being completed, which will represent one of the initial cross-platform 'omics level discovery examinations of&nbsp;lung&nbsp;tissues.&nbsp; The execution of each individual discovery platform involves&nbsp;expert local collaborators and cores&nbsp;in (epi)genetics and genomics, and the "integromics" is critically reliant on Einstein strengths in informatics and biostatistical analyses.</p>
<p>&nbsp;</p>
<p><strong>Translationally</strong>, human lung carcinogenesis biomarkers are being established by pairing laser capture microdissected lung with several unique, non-invasively collected surrogate specimens developed in the laboratory. These include mRNA expression signatures from brush-exfoliated buccal mucosa cells, microRNAs detected in exhaled breath condensate representing first reports for a new exhaled airway biomarker class, and exhaled metabolomic signatures. These airway-derived specimens continue to accrue from a sampling (currently n&gt;1000) of a population assembled in a lung cancer case-control context.&nbsp; The specimens are being studied with a view toward developing non-invasive assays in populations.</p>
<p>&nbsp;</p>
<p>The overall aim is to develop informative non-invasive risk profiling, preventive, and early disease detection strategies for the lung in human populations.</p>
<p>&nbsp;</p>
<p>&nbsp;<em>Work is funded by ongoing NIH,</em><em> DoD,&nbsp;and&nbsp;Foundation support.</em></p>
<p>&nbsp;</p>
<p><strong>Clinical Specialties</strong></p>
<ul style="font-size: 1em; color: #333333; padding: 0px; margin: 20px 0px 25px 38px;">
<li style="padding: 0px; margin: 12px 0px 5px 0px;">lung nodule evaluation</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">lung cancer diagnostics and screening</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">interstitial lung disease</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">environmental lung disease</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">refractory asthma</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">general pulmonary medicine</li>
</ul>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">A researcher and clinician, Dr. Spivack is developing tests for detecting lung cancer at the earliest possible stage&mdash;before it becomes fatal by spreading to other parts of the body. In one of several NIH-funded studies, his laboratory is working on a noninvasive, early-diagnosis test for lung cancer that detects particular genetic elements and chemicals in exhaled breath.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">In addition to general pulmonary medicine, Dr. Spivack&rsquo;s clinical practice focuses on lung nodule and lung cancer diagnosis, diffuse interstitial lung diseases, and environmental lung diseases.</span></p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Spivack specializes in consultative pulmonary medicine, with an emphasis on the evaluation of lung nodules, lung cancer screening, asthma, and environmental and interstitial lung disease.<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;"><strong></strong></span>

Research Focus

Dr. Spivack&rsquo;s research focuses on the development of non-invasive early detection airway biomarkers of lung cancer risk, as well as epigenetics, gene regulation, gene-environment interaction and non-invasive measurement of deep lung phenomena in humans.

Elsevier Profile

Selected Publications

<p>&nbsp;</p>
<p><strong><span style="text-decoration: underline;">Selected Publications, as of April, 2023</span>:</strong></p>
<p class="MsoNormal"><span style="text-indent: -0.25in;">Shi M, Han W, Loudig O, Shah C, Dobkin J, Keller S, Sadoughi A, Patel D, Desai A, Gombar S, Suh Y, Fernandez MK, DeLaRosa L, Wang T, Hosgood D, Pradhan K, Ye K, </span><strong style="text-indent: -0.25in;">Spivack SD.</strong><span style="text-indent: -0.25in;">&nbsp; </span><span style="text-indent: -0.25in;">(2023) Initial development and testing of an exhaled microRNA detection strategy for lung cancer case-control discrimination</span><em style="text-indent: -0.25in;">. [accepted, Scientific Reports, NPG]</em></p>
<p class="MsoNormal" style="margin-bottom: 1.7pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 1.7pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="color: #212121; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Huang Z, Sun S, Lee M, Maslov AY, Shi M, Waldman S, Marsh A, Siddiqui T, Dong X, Peter Y, Sadoughi A, Shah C, Ye K, *<strong>Spivack SD</strong>, *Vijg J. Single-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smoking. Nat Genet. 2022 Apr;54(4):492-498. doi: 10.1038/s41588-022-01035-w. Epub 2022 Apr 11. PMID: 35410377. (*co-senior authors).</span></p>
<p class="MsoNormal" style="margin-bottom: 1.7pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
<p class="MsoNormal"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;</span><!--[endif]--><span lang="EN">Cleven KL, Ye K, Zeig-Owens R, Hena KM, Montagna C, Shan J, Hosgood HD 3rd, Jaber N, Weiden MD, Colbeth HL, Goldfarb DG, <strong>Spivack SD</strong>++, Prezant DJ++ (++co-senior authors). </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/31126090"><span lang="EN" style="color: windowtext; text-decoration-line: none;">Genetic Variants Associated with FDNY WTC-Related Sarcoidosis.</span></a><span lang="EN"> Int J Environ Res Public Health. 2019 May 23;16(10). pii: E1830. doi: 10.3390/ijerph16101830. PMID:31126090</span>.</p>
<p>Dong X, ShiN, LeeM, ToroR, Gravina S, Han W, Yasuda S, Wang T, Zhang Z, Vijg J, Suh Y, <strong>Spivack SD.</strong> (2018) Global, integrated analysis of methylomes and transcriptomes from laser capture microdissected bronchial and alveolar cells in human lung. <em>Epigenetics </em>10.1080/15592294.2018.1441650, 2018.</p>
<p>Mullapudi N, Ye B, Suzuki M, Wang T, Fazarri M,&nbsp;Han W, Shi M, Marquardt G, Lin J, Wang T,&nbsp;Keller S, Zhu C, Locker&nbsp;J, &nbsp;<strong>Spivack SD.</strong> Genome-wide methylome alterations in lung cancer&nbsp;<em> PLoS ONE, </em>Dec. 2015.</p>
<p>Lin J, Marquardt G, Mullapudi N,&nbsp;Wang, T,&nbsp;Han W, Shi W, Zhu C, Keller S,&nbsp;Zhu C,&nbsp;Locker J, <strong>Spivack SD. </strong>Lung cancer transcriptomes refined with laser capture microdissection.<em>&nbsp;Am J Pathology </em>06.028.&nbsp;2014 .</p>
<p>Han W, Shi M, <strong>Spivack SD</strong>. Site-specific methylated reporter constructs for functional analysis of DNA methylation.<em> Epigenetics </em>4; 8(11), 2013.</p>
<p>Shi M, Han W, <strong>Spivack SD</strong>. A quantitative method to identify miRNAs targeting an mRNA using a 3'UTR RNA affinity technique.<em> Analytic Biochem</em>&nbsp;1;443(1):1-12, 2013<em>.</em></p>
<p>Alberg AJ, Brock MV, Ford JG, Samet JM, <strong>Spivack, SD.</strong>&nbsp;&nbsp;Epidemiology of lung cancer.&nbsp; In Evidence-based Practice Guidelines. Diagnosis and Management of Lung Cancer (ACCP position statement). <em>CHEST</em>.&nbsp;&nbsp;May 2013;143(5 Suppl):e1S-e29S. doi: 10.1378/chest.12-2345. PMID: 23649439.</p>
<p>Tan XT, Marquardt G, Shi M, Han W, <strong>Spivack SD.</strong> High throughput library screening identifies phytochemical inducers of phase II mutagen/oxidant metabolism enzymes GSTP1 and NQO1 in human lung cells.<em> Am J Resp Cell Molec Biol, </em>46(3): 365-71, 2012.</p>
<p>Brock GJ,&nbsp;Moschos S, <strong>Sp</strong><strong>ivack SD,</strong> Hurteau GJ.&nbsp;The 3' prime paradigm of the miR-200 family and other microRNAs. <em>Epigenetics</em> (6:3, 1-5), 2011.</p>
<p>Tan XT, &nbsp;Shi M, &nbsp;Minna JD,&nbsp; Han W,&nbsp; <strong>Spivack SD.</strong> Candidate phytopreventive agent modulation of phase II metabolism enzymes <em>GSTP1</em> and <em>NQO1</em> in human bronchial cells<em>. J Nutrition,&nbsp;</em>140(8): 1404-10, 2010<em>.</em></p>
<p>Tan, XT, &nbsp;&nbsp;Wang T,&nbsp; Xiong S,&nbsp; Kumar SV,<strong>&nbsp;</strong> Han W, &nbsp;<strong>Spivack SD.</strong> &nbsp;Smoking-related gene expression in laser capture microdissected human lung. <em>Clin Cancer Res,</em> 15(24): 7562-70, 2009.</p>
<p>Han W, Tang T, Reilly AA, Keller S, <strong>Spivack SD</strong>. Gene promoter methylation analyses from exhaled breath, with differences in smokers and lung cancer cases.&nbsp; <em>Resp Res,</em> 10:86 epubl, 2009.</p>
<p>Tan X-L,&nbsp; Moslehi R, Han W, <strong>Spivack SD</strong>. Haplotype tagging single nucleotide polymorphisms in the glutathione S-transferase P1 gene promoter and susceptibility to lung cancer. <em>Cancer Detection Prev,</em>32:403-415, 2009<em>.</em></p>
<p>Tan X-L,&nbsp;&nbsp;<strong>Spivack SD</strong>. Dietary chemoprevention strategies for&nbsp;induction of phase II metabolism: a review. <em>Lung Cancer,</em>65(2):129-37, 2009.</p>
<p>Hurteau GJ, Carlson AJ, <strong>Spivack, SD,</strong> Brock GJ. Restoration of E-Cadherin expression by over-expression of the microRNA <em>hsa-miR-200c</em> via reduced expression of the transcription factor TCF8. <em>Cancer Res.</em> 67:7972-76, 2007.</p>
<p>Hurteau, GJ, <strong>Spivack</strong> <strong>SD</strong>, Brock G.&nbsp; Parallel identification of miRNA and target mRNA by combined informatics and qRT-PCR approaches: application to <em>has-miR-200c.</em>&nbsp; <em>Cell Cycle</em> 5(17):1951-56, 2006.</p>
<p>Han W, Cauchi S, Herman JG, <strong>Spivack SD</strong>.&nbsp; Methylation mapping of DNA by tag-modified bisulfite genomic DNA sequencing. <em>Analytic Biochem. 355: 50-61,</em> 2006.</p>
<p>Cauchi S, Han W, Kumar SV, <strong>Spivack SD</strong>. Haplotype-environment interactions regulating the human <em>GSTP1</em> promoter <em>Cancer Res</em>. 66(12): 6439-6448, 2006.</p>
<p>Kumar SV, Hurteau GJ, <strong>Spivack SD.</strong> Validity of mRNA expression analyses of human saliva. <em>Clin. Cancer Res.</em> 12: 5033-39, 2006.</p>
<p><strong>Spivack SD</strong>, Hurteau GJ, Jain R, Kumar SV, Aldous KM, Gierthy JF, Kaminsky LS.&nbsp; Gene-environment interaction signatures by quantitative mRNA profiling in exfoliated buccal mucosal cells. <em>Cancer Res,</em> 64:6805-6813, 2004.</p>
<p><strong>Spivack SD</strong>, Hurteau GJ, Fasco MJ, Kaminsky LS.&nbsp; Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors.&nbsp; <em>Clinical Cancer Research</em>, 9:6002-6011, 2003.</p>
<p>&nbsp;</p>

EMR ID

4969

Biography

<p>Simon D. Spivack, MD, MPH, is Professor, Medicine, Epidemiology and Genetics at Montefiore Einstein. He is also former Emeritus Chief, Pulmonary Medicine. Clinically, Dr. Spivack specializes in consultative pulmonary medicine, with an emphasis on the evaluation of lung nodules, lung cancer screening, asthma, and environmental and interstitial lung disease. </p><p>After obtaining his Bachelor of Science in Psychobiology from McGill University in Montreal, Canada in 1980, Dr. Spivack earned his Doctor of Medicine from the State University of New York Upstate Medical University in 1985. He then completed an internship and residency in internal medicine at the University of Massachusetts Medical Center in 1988. Dr. Spivack then earned his Master of Public Health at Harvard University, School of Public Health in 1989. He completed a clinical pulmonary and critical care medicine and lung research fellowship at the University of Vermont in 1992. </p><p>Dr. Spivack&rsquo;s research focuses on the development of non-invasive early detection airway biomarkers of lung cancer risk, as well as epigenetics, gene regulation, gene-environment interaction and non-invasive measurement of deep lung phenomena in humans. His work has been published in numerous peer-reviewed journals, articles, chapters and books, and he has given many national/international presentations, organized symposia and visiting professorships. Dr. Spivack is on the Editorial Board for Scientific Reports and is a reviewer for journals such as <em>PLoS Genetics</em>, <em>Genetics in Medicine</em>, <em>Nature Protocols</em>, <em>American Journal of Respiratory &amp; Critical Care Medicine</em>, <em>Carcinogenesis</em>, <em>Cancer Research</em> and others. He holds multiple United States patents. He has been continually funded by the National Institutes of Health (NIH) for research for over 25 years.
</p><p>Dr. Spivack is board certified in internal medicine, pulmonary medicine and critical care medicine. He is a member of the American Thoracic Society (ATS), the American Association for Cancer Research (AACR) and the American Lung Association (ALA). He is a frequent peer-reviewer on various NIH study sections. In the past, Dr. Spivack won the Excellence in Research Award from ALA and the NIH/National Institute of Environmental Health Sciences (NIEHS) Clinical Scientist Development Award.

</p>

Visit Type ID

2542

Is Open Scheduling

On

Zocdoc Link

Chirag D. Shah

https://assets.montefioreeinstein.org/profiles/images/physphoto/Shah_Chirag_MD_420x504.jpg

First Name

Chirag

Last Name

Shah

NPI

1164629770

Faculty ID

15234

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5732

Visit Type ID

2542

Is Open Scheduling

On

Ali Sadoughi

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0896c190-56c0-11ec-a12b-63debfbf42ce.jpg

First Name

Ali

Last Name

Sadoughi

NPI

1699933879

Faculty ID

14807

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Ali Sadoughi is Director of Interventional Pulmonology and Bronchoscopy. His clinical expertise is in interventional pulmonology and thoracic oncology, an evolving sub-specialty of pulmonary and critical care medicine. This field focuses on patients with benign and malignant chest diseases.</p>
<p>Dr. Sadoughi performs advanced diagnostic and therapeutic procedures for patients with lung nodules/masses, intra-thoracic lymphadenopathy, pleural diseases, and severe asthma. These include:</p>
<ul>
<li>Sampling of pulmonary lesions; both peripherally and centrally located in the lung; using endobronchial ultrasound (EBUS, both radial and linear array probes) and navigational bronchoscopy</li>
<li>Therapeutic rigid and flexible bronchoscopy on patients with major airway disorders, including tumor de-bulking, airway dilatation and stent placement</li>
<li>Diagnostic and therapeutic procedures on patients with pleural disease and effusion</li>
<li>Therapeutic interventions such as pleurodesis, tunneled pleural catheter and chest tube placement</li>
<li>Bronchial thermoplasty for severe asthma&nbsp;</li>
<li>Endobronchial valve placement for persistent air leak from the lung</li>
</ul>
<p>His other&nbsp;experience is in ultrasonography and echocardiography and their applications in pulmonary and critical care medicine.</p>
<p>Dr. Sadoughi's research interests are in evolution and application of sophisticated and modern technologies for early and minimally invasive diagnosis and treatment of different pulmonary diseases, from lung cancers, to airway disorders, pulmonary hypertension, interstitial lung disease, respiratory failure, and pleural diseases. The outcome of his research studies in pulmonary hypertension and interventional pulmonology has been published in high-ranking medical journals and presented in different national conferences.</p>
<h3>Clinical Specialties</h3>
<ul>
<li>Pulmonary Medicine
<ul>
<li>Interventional Pulmonology</li>
<li>Lung Cancer</li>
</ul>
</li>
<li>Critical Care</li>
</ul>
<h3>Board Certification</h3>
<ul>
<li>Pulmonary Disease</li>
<li>Critical Care Medicine</li>
<li>Internal Medicine</li>
</ul>
<h3>Education &amp; Training</h3>
<ul>
<li>Medical School: Shahid Beheshti University of Medical Sciences</li>
<li>Residency: Kingsbrook Jewish Medical Center</li>
<li>Fellowship: Hofstra-North Shore LIJ School of Medicine</li>
<li>Fellowship: Washington University in Saint Louis</li>
</ul>
<h3>Professional Memberships</h3>
<ul>
<li>American Association of Bronchology and Interventional Pulmonology (AABIP), Member</li>
<li>American College of Chest Physicians (ACCP), Member</li>
<li>American Thoracic Society (ATS), Member</li>
<li>International Association for the Study of Lung Cancer&nbsp;(IASLC),&nbsp;Member</li>
</ul>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sadoughi specializes in interventional pulmonology, a subspecialty of pulmonary and critical care medicine that uses endoscopy and other minimally invasive tools to diagnose and treat patients with benign and malignant chest diseases.

Elsevier Profile

Selected Publications

<ol>
<li>Bronchomediastinal Fistula From Erosion of Surgical Pledgets Into the Airway, Sadoughi A, Meyers B, Chenna P, Chest. 2015;148:838A. doi:10.1378/chest.2261266</li>
<li>Obstruction of the Trachea with Necrotic Tissue from a Pleomorphic Lung Carcinoma,&nbsp;Sadoughi A, Hyman K, Patel D, Chest. 2014;146:768A. doi:10.1378/chest.1991851.</li>
<li>Diagnosis and Safe Ablation of Endobronchial Hamartoma with Interventional Bronchoscopy,&nbsp;Sadoughi A, Folch E, Majid A. Am J Respir Crit Care Med 189;2014:A4447.</li>
<li>Macrophage migration inhibitory factor mediates hypoxia- induced pulmonary hypertension, Yinzhong Zhang, Arunabh Talwar, Donna Tsang, Annette Bruchfeld, Ali Sadoughi, Maowen Hu, Kennedy Omonuwa, Kai Fan Cheng, Yousef Al-Abed, and Edmund J. Miller, Molecular Medicine, Nov 2011, PMID: 22113497.</li>
<li>Impaired Heart Rate Recovery After Cardio Pulmonary Exercise Testing [CPET] In Patients with Pulmonary Arterial Hypertension, Arunabh Talwar MD, Ali Sadoughi&nbsp; MD,&nbsp; Purvesh&nbsp; Patel MD,&nbsp; Tara George, Donna Tsang, Nina Kohn MS; Chest. 2011;140(4_MeetingAbstracts):723A. doi:10.1378/chest.1119783</li>
<li>A 77-year-old woman with dyspnea and Reynaud phenomenon. Wang J, Sadoughi A, Dedopoulos S, Talwar A, Chest. 2011 Apr;139(4):958-6. PMID: 21467065</li>
<li>Intracranial Pressure Treatment Tailored to Transcranial Doppler-Derived Compliance and Perfusion. Kapinos G, Sadoughi A, Narayan R, oral presentation, November 2013 at the 15th International Conference on Intracranial Pressure and Brain Monitoring, Singapore.</li>
<li>Management of Increased Intracranial Pressure. Sadoughi A, Rybinnik I, Cohen R. The Open Critical Care Medicine Journal, 2013, 6, (Suppl 1: M4) 56-65.</li>
<li>Use of Selective Serotonin Reuptake Inhibitors and Outcomes in Pulmonary Arterial Hypertension, Sadoughi A, Roberts K, Preston I, Lai GP, Mcollister D, Farber HW, Hill NS, Chest. 2013 Apr 4. PMID: 23558791.</li>
<li>Inflammatory Mechanisms in Pulmonary Hypertension, A Sadoughi, Y Zhang, EJ Miller, A Talwar; <em>CML (Current Medical Literature) &ndash; Pulmonary Hypertension </em>2010;1(4):93&ndash;106.</li>
<li>Computed Tomography Angiogram of the Chest as a Valuable Predicting Tool for Pulmonary Arterial Hypertension, A Sadoughi, N Patel, J Wang, N Kohn, R Shah, A Talwar; Chest. 2010;138(4_MeetingAbstracts):357A. doi:10.1378/chest.10559</li>
<li>Arterial Concentration of Macrophage Migration Inhibitory Factor (MIF) increases with exercise in patients with pulmonary Hypertension (PH), A Sadoughi, EJ Miller, A Talwar, presented at FOCIS 2011, Washington, DC.</li>
<li>Utility of Pulmonary Artery Diameter in Computed Tomography of Chest as a screening tool for Pulmonary Arterial Hypertension, A Sadoughi, T Chandak, N Kohn, R Shah, A Talwar, Presented in ATS Meeting, May 2010.</li>
<li>Relationship of Pulmonary Arterial Oxygen Saturation with Right Atrial Pressure in Pulmonary Hypertension, T Chandak, A Sadoughi, N Kohn, A Talwar, Presented in ATS Meeting, May 2010.</li>
<li>A case of Portopulmonary Hypertension, Sadoughi A, Mukherji R, Mehra S, Talwar A, The Journal of Respiratory Diseases, September, 2008.</li>
<li>Arteriotomy Closure Device Application Following Percutaneous Coronary Intervention May Prevent Bleeding Complication in Patients with Acute Myocardial Infarction, F. Ikeno, M. Ali Sadoughi, J. Lyons, F. Raissi, K. Pourdehmobed, V. Hashemi, S. Emami, H. Kaneda, A. C. Yeung, M. Rezaee, International J. of Cardiology, April 2007, 117(1), 131-132, PMID:16935367.</li>
<li>The Conversion in Application of Percutaneous Coronary Intervention Following the Introduction of Drug Eluting Stents, F. Ikeno, F. Raissi, M. Ali Sadoughi, J.K. Lyons, K. Pourdehmobed, V. Hashemi, S. Emami, H. Kanada, A.C. Yeung, M. Rezaee, International Journal of Cardiology, November 2006, 113(2), 279-280, PMID: 16318883.</li>
<li>Drug-eluting stents alter referral patterns for revascularization in patients with multivessel coronary artery disease, HMO Farouque, Fearon WF, Wu BM, Luna J, Shabari FR, Sadoughi MA, Lee DP, Yeung AC, Heart, Lung, Circulation 2005; 14 Suppl 1: S77, Australia</li>
<li>Changes in the Practice of Percutaneous Coronary Intervention Following the Introduction of Drug Eluting Stents, Raissi F., Sadoughi M.A., Hashemi V., Pourdehmobed K., Farouque O., Lyons J., Emami S., Ikeno F., Kaneda H., Yeung A.C., Rezaee M., TCT (Transcatheter Cardiovascular Therapeutics) meeting 2004, Washington DC, Poster Presentation, 09 / 2004.</li>
</ol>

EMR ID

78160

Biography

<p>Ali Sadoughi, MD, is Director, Interventional Pulmonology and Bronchoscopy and Associate Professor, Medicine at Montefiore Einstein. He specializes in interventional pulmonology, a subspecialty of pulmonary and critical care medicine that uses endoscopy and other minimally invasive tools to diagnose and treat patients with benign and malignant chest diseases.</p><p>After earning his Doctor of Medicine at Shahid Beheshti University of Medical Sciences in Tehran, Iran, Dr. Sadoughi completed an internal medicine residency at Kingsbrook Jewish Medical Center. Following this, he completed a pulmonary and critical care fellowship at Hofstra-North Shore LIJ School of Medicine in 2014 and an interventional pulmonary fellowship at Washington University in 2015.</p><p>Dr. Sadoughi's research interests are in developing and applying advanced technologies for early and minimally invasive diagnosis and treatment of pulmonary diseases. These include lung cancers, airway disorders, pulmonary hypertension, interstitial lung disease, respiratory failure and pleural diseases. His work has been published in journals including <em>Chest</em> and the <em>Journal of Molecular Medicine</em>, and he has made presentations at national and international medical meetings. One of his recent research studies focuses on the development of brachytherapy seeds (DaRT) using alpha radiation for the treatment of lung cancer, sponsored by Alpha Tau Ltd. In another study, he works with an international group of pulmonologists on the role of confocal laser endomicroscopy (CLE) in the diagnosis of different benign and malignant lung diseases. His work related to increased precision and accuracy of biopsy of peripheral lung nodules by intraprocedural 3D scanning in combination with ultrathin bronchoscopy has been published in the <em>Journal of Bronchology and Interventional Pulmonology</em>. Another area of Dr. Sadoughi&rsquo;s research involves the synergy of local therapies such as cryotherapy with immunotherapy in the treatment of lung cancer. He has presented this exciting topic at the American Association of Bronchology and Interventional Pulmonology (AABIP) Conference in 2022.</p><p>Dr. Sadoughi is board certified in interventional pulmonology, pulmonary disease, critical care medicine and internal medicine. He is a member of professional societies such as the American Association of Bronchology and Interventional Pulmonology, the World Association of Bronchology and Interventional Pulmonology, the American College of Chest Physicians, the American Thoracic Society and the International Association for the Study of Lung Cancer. He has contributed his research to the U.S. News, Politico New York and OncLive, and has been an editorial member and reviewer of multiple medical journals.</p>

Is Open Scheduling

On